Merck Announces JAMA Publication of Phase II Results of Sprifermin for Osteoarthritis Structure Modification

Posted in Biotech by Medtech[y] Staff

October 08, 2019 • 2 min read

Merck, a leading science and technology company, today announced that results from FORWARD, a five-year, multicentre Phase II study of sprifermin, a recombinant human fibroblast growth factor-18, in patients with symptomatic radiographic knee osteoarthritis (OA) were published online in the Journal of the American Medical Association (JAMA). ...

Gilead Presents New Data From the Company’s HIV Clinical Development Program and Latest Findings on the Impact of HIV Pre-exposure Prophylaxis (PrEP) at IDWeek 2019

Posted in Biotech by Medtech[y] Staff

October 04, 2019 • 2 min read

Results from DISCOVER Trial Provide Bone and Renal Safety Profile Data from Participants who Switched from Truvada for PrEP® to Descovy for PrEP. Analysis Illustrates the Significant and Independent Impact of High PrEP Use on HIV Diagnoses Rate in Major U.S. Cities -...